ReviewBioengineered
Production of biopharmaceutical proteins by yeast: advances through metabolic engineering.
Review in Bioengineered. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 91 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
91 citing papers in PubMed, 268 citations in OpenAlex.
- Trial
- The impact of evolutionary dynamics and expression plasmid stability on long-term heterologous protein production by yeast.Microbial cell factories · 2026Article
- Article
- Dual spatio-functional control of a fission yeast-based bioprocessor upon chemical induction.RSC chemical biology · 2026Article
- A time-resolved high-throughput screening of fission yeast deletion mutants for oxidative stress resistance.Microbial cell (Graz, Austria) · 2026Article
- A reconstruction of the mammalian secretory pathway identifies mechanisms regulating antibody production.Cell systems · 2025Article
- PIONEER: A Periplasmic Display Platform for Synthetic Biology-Based Screening of Genetically Encoded Protein Regulators.bioRxiv : the preprint server for biology · 2025Article
- YTK Display-and-Secrete: Screening for Optimal Protein Secretion Elements inACS synthetic biology · 2025Article
- Genomic and phenotypic comparison ofbioRxiv : the preprint server for biology · 2025Article
- Identification of improved signal peptides for heterologous expression in Saccharomyces using a screen that exploits Gaussia luciferase.Scientific reports · 2025Article
- Effect of recombinant protein production and release on microalgal fitness and the impact of environmental conditions for localized therapeutic delivery.Journal of biological engineering · 2025Article
- Automation of RNA-Seq Sample Preparation and Miniaturized Parallel Bioreactors Enable High-Throughput Differential Gene Expression Studies.Microorganisms · 2025Article
- A thermostable and highly active fungal GH3 β-glucosidase generated by random and saturation mutagenesis.Proceedings of the Japan Academy. Series B, Physical and biological sciences · 2025Article
- Mining yeast diversity unveils novel targets for improved heterologous laccase production in Saccharomyces cerevisiae.Microbial cell factories · 2025Article
- Engineering Useful Microbial Species for Pharmaceutical Applications.Microorganisms · 2025Review
- Lighting up yeast: overview of optogenetics in yeast and their applications to yeast biotechnology.FEMS yeast research · 2025Review
- Transforming non-conventional yeasts into key players in biotechnology: advances in synthetic biology applications.Frontiers in microbiology · 2025Review
- A versatile genetic toolkit for engineeringFrontiers in bioengineering and biotechnology · 2025Article
- Modeling for understanding and engineering metabolism.QRB discovery · 2025Article
- Genes controlling hydrolysate toxin tolerance identified by QTL analysis of the natural Saccharomyces cerevisiae BCC39850.Applied microbiology and biotechnology · 2024Article
31 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 3 countries.
Funding
Abstract
Production of recombinant proteins for use as pharmaceuticals, so-called biopharmaceuticals, is a multi-billion dollar industry. Many different cell factories are used for the production of biopharmaceuticals, but the yeast Saccharomyces cerevisiae is an important cell factory as it is used for production of several large volume products. Insulin and insulin analogs are by far the dominating biopharmaceuticals produced by yeast, and this will increase as the global insulin market is expected to grow from USD12B in 2011 to more than USD32B by 2018. Other important biopharmaceuticals produced by yeast are human serum albumin, hepatitis vaccines and virus like particles used for vaccination against human papillomavirus. Here is given a brief overview of biopharmaceutical production by yeast and it is discussed how the secretory pathway can be engineered to ensure more efficient protein production. The involvement of directed metabolic engineering through the integration of tools from genetic engineering, systems biology and mathematical modeling, is also discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.